Pancreatic cancer trial combines immunotherapy and targeted drug to boost treatment
Disease control
Completed
This study tested whether adding two drugs—pembrolizumab (an immunotherapy) and defactinib (a targeted therapy)—to standard chemotherapy could help the immune system fight pancreatic cancer better. The treatment was given before and after surgery to 28 people with resectable panc…
Phase: PHASE2 • Sponsor: Lei Zheng • Aim: Disease control
Last updated May 13, 2026 15:59 UTC